Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 6/20 | 0.50 |
| ▸ | CYP24A1 | Q07973 | 8/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | CYP27B1 | O15528 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6983161 | 0.88 | CYP24A1 (0.56) | CYP17A1CYP24A1HSD17B10POLBSMN1; SMN2 | |
| SCHEMBL20830319 | 0.86 | CYP19A1 (0.59) | CYP17A1CYP24A1SMN1; SMN2TDP1CYP19A1 | |
| SCHEMBL18123005 | 0.86 | CYP19A1 (0.59) | CYP17A1CYP24A1SMN1; SMN2TDP1CYP19A1 | |
| SCHEMBL19054892 | 0.85 | CYP17A1 (0.68) | CYP17A1CYP24A1TDP1CYP19A1CYP27B1 | |
| SCHEMBL21976264 | 0.83 | CYP26A1 (0.60) | CYP17A1CYP24A1 | |
| SCHEMBL19999185 | 0.82 | CYP17A1 (0.50) | CYP17A1CYP24A1CYP19A1 | |
| SCHEMBL19054886 | 0.82 | CYP19A1 (0.55) | CYP17A1HSD17B10POLBSMN1; SMN2TDP1 | |
| SCHEMBL20390007 | 0.81 | CYP17A1 (0.46) | CYP17A1CYP24A1SMN1; SMN2CYP19A1 | |
| SCHEMBL21419726 | 0.79 | MMP9 (0.55) | CYP17A1POLBSMN1; SMN2TDP1CYP19A1 | |
| SCHEMBL21419727 | 0.79 | MMP9 (0.55) | CYP17A1POLBSMN1; SMN2TDP1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718587-B2 | Compound, epoxy curing catalyst and method for producing compound | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-08-08 | — | — | US | disclosed |
| US-11718587-B2 | Compound, epoxy curing catalyst and method for producing compound | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-08-08 | — | — | US | disclosed |
| WO-2021220919-A1 | METHOD FOR PRODUCING SURFACE-MODIFIED METAL OXIDE MICROPARTICLES, METHOD FOR PRODUCING SURFACE-MODIFIED METAL OXIDE MICROPARTICLE DISPERSION, AND METHOD FOR PRODUCING SOLID PRODUCT | 東京応化工業株式会社 | 2021-11-04 | — | — | WO | disclosed |
| WO-2021220920-A1 | METHOD FOR PRODUCING SURFACE-MODIFIED METAL OXIDE MICROPARTICLES, SURFACE-MODIFIED METAL OXIDE MICROPARTICLES, SURFACE-MODIFIED METAL OXIDE MICROPARTICLE DISPERSION, SOLID PRODUCT, METHOD FOR PRODUCING SURFACE-MODIFIED METAL OXIDE MICROPARTICLE DISPERSION, AND METHOD FOR PRODUCING SOLID PRODUCT | 東京応化工業株式会社 (JP) | 2021-11-04 | — | — | WO | disclosed |
| US-10696845-B2 | Energy-sensitive resin composition | TOKYO OHKA KOGYO CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| US-20200139433-A1 | METHOD FOR PRODUCING SURFACE-MODIFIED METAL OXIDE FINE PARTICLE, METHOD FOR PRODUCING IMPROVED METAL OXIDE FINE PARTICLES, SURFACE-MODIFIED METAL OXIDE FINE PARTICLES, AND METAL OXIDE FINE PARTICLE DISPERSION LIQUID | TOKYO OHKA KOGYO CO., LTD. (JP) | 2020-05-07 | — | — | US | disclosed |
| US-10570269-B2 | Composition containing microparticles | TOKYO OHKA KOGYO CO., LTD. (JP) | 2020-02-25 | — | — | US | disclosed |
| US-20190225804-A1 | ENERGY-SENSITIVE RESIN COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2019-07-25 | — | — | US | disclosed |
| US-10336708-B2 | Imidazole compound, metal surface treatment liquid, metal surface treatment method, and laminate production method | TOKYO OHKA KOGYO CO., LTD. (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20180194930-A1 | COMPOSITION CONTAINING MICROPARTICLES | TOKYO OHKA KOGYO CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180194930-A1 | COMPOSITION CONTAINING MICROPARTICLES | TOKYO OHKA KOGYO CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20170247334-A1 | IMIDAZOLE COMPOUND, METAL SURFACE TREATMENT LIQUID, METAL SURFACE TREATMENT METHOD, AND LAMINATE PRODUCTION METHOD | TOKYO OHKA KOGYO CO., LTD. (JP) | 2017-08-31 | — | — | US | disclosed |
| US-20170247334-A1 | IMIDAZOLE COMPOUND, METAL SURFACE TREATMENT LIQUID, METAL SURFACE TREATMENT METHOD, AND LAMINATE PRODUCTION METHOD | TOKYO OHKA KOGYO CO., LTD. (JP) | 2017-08-31 | — | — | US | disclosed |
| EP-3184511-A1 | IMIDAZOLE COMPOUND, METAL SURFACE TREATMENT LIQUID, METAL SURFACE TREATMENT METHOD, AND LAMINATE PRODUCTION METHOD | Tokyo Ohka Kogyo Co., Ltd. (JP) | 2017-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336708-B2 | Imidazole compound, metal surface treatment liquid, metal surface treatment method, and laminate production method | FASN, SLC27A1, SLC27A2 | CYP17A1 1258/4885CYP24A1 1784/4885HSD17B10 555/4885 |
| US-20180194930-A1 | COMPOSITION CONTAINING MICROPARTICLES | CHMP4B, EXOSC10, EXOSC9 | CYP17A1 4321/4885CYP24A1 3200/4885HSD17B10 4476/4885 |
| US-20170247334-A1 | IMIDAZOLE COMPOUND, METAL SURFACE TREATMENT LIQUID, METAL SURFACE TREATMENT METHOD, AND LAMINATE PRODUCTION METHOD | FASN, SLC27A1, SLC27A2 | CYP17A1 1258/4885CYP24A1 1784/4885HSD17B10 555/4885 |
| US-11718587-B2 | Compound, epoxy curing catalyst and method for producing compound | MSMO1, RIOK1, ME1 | CYP17A1 369/4885CYP24A1 2215/4885HSD17B10 2419/4885 |
| US-10570269-B2 | Composition containing microparticles | CHMP4B, EXOSC10, EXOSC9 | CYP17A1 4321/4885CYP24A1 3200/4885HSD17B10 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.